Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabrizio Stocchi

Showing results (21-30 of 253) with videos related to

Pageof 26
Sort By:
Neurology|January 14, 2004
COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications?C Warren Olanow, Fabrizio Stocchi
Movement Disorders : Official Journal of the Movement Disorder Society|February 8, 2013
Obstacles to the development of a neuroprotective therapy for Parkinson's diseaseFabrizio Stocchi, C Warren Olanow
Annals of Neurology|April 1, 2003
Neuroprotection in Parkinson's disease: clinical trialsFabrizio Stocchi, C Warren Olanow
Movement Disorders : Official Journal of the Movement Disorder Society|November 28, 2017
Levodopa: A new look at an old friendC Warren Olanow, Fabrizio Stocchi
Expert Opinion on Pharmacotherapy|September 21, 2018
Istradefylline for the treatment of Parkinson's disease: is it a promising strategy?Margherita Torti, Laura Vacca, Fabrizio Stocchi
Advances in Neurology|November 22, 2002
Are there clinically significant differences between dopamine agonistsFabrizio Stocchi, Laura Vacca, Marco Onofrj
Clinical Interventions in Aging|December 1, 2007
Utility of tolcapone in fluctuating Parkinson's diseaseFabrizio Stocchi, Maria Francesca De Pandis
Expert Opinion on Pharmacotherapy|August 26, 2016
Advances in dopamine receptor agonists for the treatment of Parkinson's diseaseFabrizio Stocchi, Margherita Torti, Chiara Fossati
Expert Opinion on Pharmacotherapy|September 15, 2015
Rasagiline for the treatment of Parkinson's disease: an updateFabrizio Stocchi, Chiara Fossati, Margherita Torti
Expert Opinion on Drug Safety|September 2, 2020
Safety considerations when using non-ergot dopamine agonists to treat Parkinson's diseaseFabrizio Stocchi, Barbara Fossati, Margherita Torti
Pageof 26

Showing results (21-30 of 253) with videos related to

Sort By:
Pageof 26
Neurology|January 14, 2004
COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications?C Warren Olanow, Fabrizio Stocchi
Movement Disorders : Official Journal of the Movement Disorder Society|February 8, 2013
Obstacles to the development of a neuroprotective therapy for Parkinson's diseaseFabrizio Stocchi, C Warren Olanow
Annals of Neurology|April 1, 2003
Neuroprotection in Parkinson's disease: clinical trialsFabrizio Stocchi, C Warren Olanow
Movement Disorders : Official Journal of the Movement Disorder Society|November 28, 2017
Levodopa: A new look at an old friendC Warren Olanow, Fabrizio Stocchi
Expert Opinion on Pharmacotherapy|September 21, 2018
Istradefylline for the treatment of Parkinson's disease: is it a promising strategy?Margherita Torti, Laura Vacca, Fabrizio Stocchi
Advances in Neurology|November 22, 2002
Are there clinically significant differences between dopamine agonistsFabrizio Stocchi, Laura Vacca, Marco Onofrj
Clinical Interventions in Aging|December 1, 2007
Utility of tolcapone in fluctuating Parkinson's diseaseFabrizio Stocchi, Maria Francesca De Pandis
Expert Opinion on Pharmacotherapy|August 26, 2016
Advances in dopamine receptor agonists for the treatment of Parkinson's diseaseFabrizio Stocchi, Margherita Torti, Chiara Fossati
Expert Opinion on Pharmacotherapy|September 15, 2015
Rasagiline for the treatment of Parkinson's disease: an updateFabrizio Stocchi, Chiara Fossati, Margherita Torti
Expert Opinion on Drug Safety|September 2, 2020
Safety considerations when using non-ergot dopamine agonists to treat Parkinson's diseaseFabrizio Stocchi, Barbara Fossati, Margherita Torti
Pageof 26